Royalty Pharma published press releases by date and/or category

Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

NEW YORK, NY and SOUTH SAN FRANCISCO, CA, May 22, 2024 – Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company’s expanding cardiovascular pipeline while diversifying access to capital as the company advances its muscle biology-directed specialty cardiology business.

Royalty Pharma Announces Dividend Increase

NEW YORK, NY, January 19, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2024 of $0.21 per Class A share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend.

Stay up to date

Subscribe to Royalty Pharma news and alerts